THERAPEUTIC AGENT FOR PARKINSON'S DISEASE

摘要

A medicine for the prevention, treatment, and/or symptom progress inhibition of Parkinson's disease and/or Parkinson's syndrome. It comprises a combination of (2R)-2-propyloctanoic acid, a salt or solvate thereof, or a prodrug of either with an agent for the prevention, treatment, and/or symptom progress inhibition of Parkinson's disease and/or Parkinson's syndrome. The medicine is highly effective in the prevention, treatment, and/or symptom progress inhibition of Parkinson's disease and/or Parkinson's syndrome. In particular, when the medicinal composition which is for oral administration, which contains (2R)-2-propyloctanoic acid, a salt or solvate thereof, or a prodrug of either as an active ingredient, is administered in combination with a levodopa preparation, levodopa/benserazide preparation, levodopa/carbidopa preparation, and/or bromocriptine mesilate in the manner and dose shown in the description, then effects unobtainable with conventional treatments can be produced, such as a dose reduction, alleviation of side effects, and therapeutic-effect enhancement.